NHI director granted 1,268 restricted shares

Todd Candice W reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/05/2026 - 05:21 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Todd Candice W reported acquisition or exercise transactions in this Form 4 filing.

National Health Investors Inc. director Candice W. Todd received a grant of 1,268 shares of common stock on March 3, 2026. This restricted stock award vests in full on March 3, 2027, if she continues serving as a director through that date, bringing her direct holdings to 2,563 shares.

Insider Trade Summary

Grant/Award: 1,268 shares

Grant/Award 1 txn

Insider Todd Candice W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,268	$0.00	$0.00

Holdings After Transaction: Common Stock — 2,563 shares (Direct)

Holdings Before and After: Common Stock, 1,295 to 2,563 shares (Direct)

Footnotes (1)

F1. Represents a grant of restricted stock awarded on March 3, 2026, which vests in full on March 3, 2027, subject to the reporting person's continued service as a director through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did NHI director Candice W. Todd report on this Form 4?

Candice W. Todd reported receiving a grant of 1,268 shares of National Health Investors common stock. The shares were awarded on March 3, 2026 as restricted stock, increasing her direct ownership to a total of 2,563 shares after the transaction.

When do the restricted shares granted to NHI director Candice W. Todd vest?

The 1,268 restricted shares granted to Candice W. Todd vest in full on March 3, 2027. Vesting is conditioned on her continued service as a director through that date, aligning the award with ongoing board tenure and performance.

Was there a purchase price for the NHI restricted stock granted to Candice W. Todd?

The reported transaction lists a price per share of 0.0000, indicating the 1,268 shares were issued as a grant rather than an open-market purchase. This reflects typical director equity compensation structured as restricted stock awards.

How many NHI shares does Candice W. Todd own after the reported grant?

Following the restricted stock grant, Candice W. Todd directly owns 2,563 shares of National Health Investors common stock. This total includes the newly awarded 1,268 shares, as disclosed in the Form 4 ownership figures after the transaction.

What type of transaction code was used for Candice W. Todd’s NHI stock grant?

The transaction is coded as “A,” meaning a grant, award, or other acquisition. It represents a non-derivative acquisition of 1,268 shares of common stock, categorized as a restricted stock award granted to her in her capacity as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Todd Candice W

(Last)

(First)

(Middle)

222 ROBERT ROSE DR

(Street)

MURFREESBORO

37129

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
NATIONAL HEALTH INVESTORS INC [ NHI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/03/2026		A		1,268⁽¹⁾	A	$0	2,563	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a grant of restricted stock awarded on March 3, 2026, which vests in full on March 3, 2027, subject to the reporting person's continued service as a director through such date.

	/s/ Kimberly V. Ouimet, by limited power of attorney	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR